Methylene Blue Anhydrous
CAS 61-73-4
Methylene Blue Anhydrous (CAS 61-73-4) is a Phase 4 pharmaceutical compound with 8 bioactivity targets and 23 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 20959.196428571428 nM | 82 | - |
| - | IC50 | 14865.885 nM | 60 | - |
| - | Potency | 14744.154166666667 nM | 45 | - |
| - | EC50 | 7623.911111111111 nM | 18 | - |
| - | IC50 | 4478.547272727273 nM | 10 | - |
| - | AC50 | 16383.144444444442 nM | 9 | - |
| - | MIC | 202 ug.mL-1 | 8 | - |
| - | Kd | 9533.333333333334 nM | 3 | - |
| - | EC50 | 400 nM | 1 | - |
| Glutathione reductase, mitochondrial Enzyme |
IC50 | 4.8 | - | Homo sapiens |
| Amine oxidase [flavin-containing] B Enzyme |
IC50 | 5.36 | - | Homo sapiens |
| Amine oxidase [flavin-containing] A Enzyme |
IC50 | 7.15 | - | Homo sapiens |
| Thioredoxin reductase 1, cytoplasmic Enzyme |
IC50 | 4.52 | - | Homo sapiens |
| Glutathione reductase Enzyme |
IC50 | 5.19 | - | Plasmodium falciparum (isolate 3D7) |
| Cruzipain Enzyme |
IC50 | 4.26 | - | Trypanosoma cruzi |
| Microtubule-associated protein tau Structural |
IC50 | 5.72 | - | Homo sapiens |
| Amyloid beta A4 protein Unclassified |
IC50 | 6.26 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Serotonin syndrome | 417 | 1802.228 | 10040108 |
| Drug interaction | 294 | 523.304 | 10013710 |
| Myoglobin urine present | 53 | 324.343 | 10028631 |
| Toxic encephalopathy | 69 | 267.539 | 10044221 |
| Amylase increased | 53 | 189.865 | 10002016 |
| Troponin increased | 53 | 163.025 | 10058267 |
| Clonus | 41 | 157.162 | 10009346 |
| Vasoplegia syndrome | 35 | 151.475 | 10067080 |
| Blood potassium increased | 54 | 140.622 | 10005725 |
| Hyperreflexia | 39 | 140.288 | 10020745 |
| Blood creatine phosphokinase increased | 67 | 140.096 | 10005470 |
| Encephalopathy | 63 | 128.117 | 10014625 |
| Blood lactate dehydrogenase increased | 53 | 122.54 | 10005630 |
| Nystagmus | 33 | 106.296 | 10029864 |
| Coma | 64 | 105.271 | 10010071 |
| Hypotension | 108 | 88.445 | 10021097 |
| Mydriasis | 32 | 85.307 | 10028521 |
| Agitation | 53 | 76.443 | 10001497 |
| Overdose | 66 | 70.822 | 10033295 |
| Coma scale abnormal | 23 | 69.794 | 10069709 |
| Alanine aminotransferase increased | 59 | 66.709 | 10001551 |
| Methaemoglobinaemia | 20 | 65.767 | 10027496 |
| Metabolic acidosis | 43 | 65.04 | 10027417 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| METHYLENE BLUE ANHYDROUS | 2198975 | SU | MTHSPL |
| methylene blue anhydrous | 2198975 | PIN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Methylene Blue Anhydrous used for in pharmaceutical contexts?
Methylene Blue Anhydrous (CAS 61-73-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Methylene Blue Anhydrous?
Methylene Blue Anhydrous has 23 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Serotonin syndrome, Drug interaction, Myoglobin urine present, Toxic encephalopathy, Amylase increased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Methylene Blue Anhydrous also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Basic Blue 9 (Methylene Blue) with EU status "permitted".
What clinical phase is Methylene Blue Anhydrous in?
Methylene Blue Anhydrous is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Methylene Blue Anhydrous?
Methylene Blue Anhydrous has 17 bioactivity rows in this page query. Rendered target entries include Glutathione reductase, mitochondrial, Amine oxidase [flavin-containing] B, Amine oxidase [flavin-containing] A, Thioredoxin reductase 1, cytoplasmic, Glutathione reductase.